Genetic ablation of NADPH oxidase enhances susceptibility to cigarette smoke-induced lung inflammation and emphysema in mice.

Department of Environmental Medicine, Lung Biology and Disease Program, University of Rochester Medical Center, Box 850, 601 Elmwood Ave., Rochester, NY 14642, USA.
American Journal Of Pathology (Impact Factor: 4.6). 06/2008; 172(5):1222-37. DOI: 10.2353/ajpath.2008.070765
Source: PubMed

ABSTRACT Cigarette smoke (CS) induces recruitment of inflammatory cells in the lungs leading to the generation of reactive oxygen species (ROS), which are involved in lung inflammation and injury. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is a multimeric system that is responsible for ROS production in mammalian cells. We hypothesized that NADPH oxidase-derived ROS play an important role in lung inflammation and injury and that targeted ablation of components of NADPH oxidase (p47(phox) and gp91(phox)) would protect lungs against the detrimental effects of CS. To test this hypothesis, we exposed p47(phox-/-) and gp91(phox-/-) mice to CS and examined inflammatory response and injury in the lung. Surprisingly, although CS-induced ROS production was decreased in the lungs of p47(phox-/-) and gp91(phox-/-) mice compared with wild-type mice, the inflammatory response was significantly increased and was accompanied by development of distal airspace enlargement and alveolar destruction. This pathological abnormality was associated with enhanced activation of the TLR4-nuclear factor-kappaB pathway in response to CS exposure in p47(phox-/-) and gp91(phox-/-) mice. This phenomenon was confirmed by in vitro studies in which treatment of peritoneal macrophages with a nuclear factor-kappaB inhibitor reversed the CS-induced release of proinflammatory mediators. Thus, these data suggest that genetic ablation of components of NADPH oxidase enhances susceptibility to the proinflammatory effects of CS leading to airspace enlargement and alveolar damage.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Influenza A viruses represent a major global healthcare challenge with imminent pandemics, emerging anti-viral resistance and long lag times for vaccine development raising a pressing need for novel pharmacological strategies that ideally target the pathology irrespective of the infecting strain. Reactive oxygen species (ROS) pervade all facets of cell biology with both detrimental and protective properties. Indeed there is compelling evidence that activation of the nicotinamide adenine dinucleotide phosphate-oxidase NADPH oxidase 2 (NOX2) isoform of the NADPH oxidase family of ROS-producing enzymes promotes lung oxidative stress, inflammation, injury and dysfunction to influenza A viruses of low to high pathogenicity, as well as impeding virus clearance. By contrast the NOX1 and DUOX isoforms produce ROS that provide vital protective antiviral effects for the host. In this review, we propose the concept that inhibitors of NOX2 are better alternatives than broad-spectrum antioxidant approaches for treatment of influenza pathologies, for which clinical efficacy may have been limited owing to poor bioavailability and inadvertent removal of beneficial ROS. Finally, we briefly describe the current suite of NADPH oxidase inhibitors and the molecular features of the NADPH oxidase enzymes that could be exploited by drug discovery for development of more specific and novel inhibitors to prevent or treat disease caused by influenza.
    Molecular pharmacology 10/2014; DOI:10.1124/mol.114.095216 · 4.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin II (ATII), acting via Type I ATII receptors (AT1R), promotes vasoconstriction of vascular smooth muscle; hence, angiotensin antagonist drugs, i.e., angiotensin receptors blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors, are employed in the management of hypertension. However, AT1R stimulation also activates nicotinamide adenine dinucleotide phosphate oxidase complexes in a range of tissues, via joint stimulation of protein kinase C and Rac. Angiotensin antagonist drugs therefore function as “source antioxidants” preventing oxidative stress at its source by blocking superoxide production. This phenomenon may explain why these drugs have been found to convey a range of health benefits that are at least partially independent of their impact on blood pressure. These benefits appear to include: A reduction in risk for Type 2 diabetes; an improvement in endothelial function; reduced risk for vascular disorders including atrial fibrillation, left ventricular hypertrophy and aortic aneurysms; reduced mortality in, and a possible preventive impact on, chronic obstructive pulmonary disease; slowed progression of kidney disease; slowed progression of diabetic neuropathy and retinopathy; decreased risk for non-alcoholic fatty liver disease; neuroprotective effects which may aid prevention of Parkinson’s and Alzheimer’s diseases; and an inhibitory impact on induction and spread of prostate cancer. There is reason to suspect that each of these benefits is largely attributable to the source antioxidant activity of ARB and ACE inhibitors. In light of the versatility of the protection afforded by these drugs, and the low risk for side effects with ARB, consideration should be given to the possibility of using ARB as a preventive measure in the general population (excluding pregnant women), in non-hypertensives and hypertensives alike - perhaps as a component of a “polypill.” Moreover, the broadly favorable clinical experience with angiotensin antagonist drugs suggests that source antioxidants as a class may have far greater potential for preserving health than antioxidants which merely act as oxidant scavengers.
    03/2015; 4(1):1-16. DOI:10.5455/oams.180115.rv.015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Reactive oxygen species (ROS) participate in the pathogenesis of emphysema. Among ROS-producing enzymes, NOX NADPH oxidases are thought to be responsible for tissue injury associated with several lung pathologies. To determine whether NOX2 and/or NOX1 participate in the development of emphysema, their expression patterns were first studied by immunohistochemistry in lungs of emphysematous patients. Subsequently, we investigated their contribution to elastase-induced emphysema using NOX2- and NOX1-deficient mice.In human lung, NOX2 was mainly detected in macrophages of control and emphysematous lungs, while NOX1 was expressed in alveolar epithelium and bronchial cells. We observed an elevated number of NOX2-positive cells in human emphysematous lungs, as well as an increased NOX2 and NOX1 mRNA expression in mouse lungs following elastase exposure. Elastase-induced alveolar airspace enlargement and elastin degradation were prevented in NOX2-deficient mice, but not in NOX1-deficient mice. This protection was independent of inflammation and correlated with reduced ROS production. Concomitantly, an elevation of sirtuin 1 (SIRT1) level and a decrease of matrix metalloproteinase-9 (MMP-9) expression and activity were observed in alveolar macrophages and neutrophils. We addressed the specific role of macrophage-restricted functional NOX2 in elastase-induced lung emphysema using Ncf1 mutant mice and Ncf1 macrophage rescue mice (Ncf1 mutant mice with transgenic expression of Ncf1 only in CD68-positive mononuclear phagocytes; the MN mouse). Compared to WT mice, the lack of functional NOX2 led to decreased elastase-induced ROS production, and protected against emphysema. In contrast, ROS production was restored specifically in macrophages from Ncf1 rescue mice and contributes to emphysema.Taken together, our results demonstrate that NOX2 is involved in the pathogenesis of human emphysema and macrophage-specific NOX2 participates in elastase-induced emphysema through the involvement of SIRT1/MMP-9 pathways in mice.
    The Journal of Pathology 11/2014; DOI:10.1002/path.4423 · 7.33 Impact Factor


Available from
May 29, 2014